Omeros - 16 Year Stock Price History | OMER
Historical daily share price chart and data for Omeros since 2009 adjusted for splits and dividends. The latest closing stock price for Omeros as of November 18, 2025 is 8.50.
- The all-time high Omeros stock closing price was 26.69 on September 04, 2018.
- The Omeros 52-week high stock price is 13.60, which is 60% above the current share price.
- The Omeros 52-week low stock price is 2.95, which is 65.3% below the current share price.
- The average Omeros stock price for the last 52 weeks is 6.46.
| Omeros Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2025 | 6.0071 | 9.8400 | 11.2100 | 2.9700 | 8.5000 | -13.97% |
| 2024 | 4.6401 | 3.2900 | 12.1500 | 2.8800 | 9.8800 | 202.14% |
| 2023 | 3.8862 | 2.4800 | 7.5700 | 1.0800 | 3.2700 | 44.69% |
| 2022 | 4.2523 | 6.9900 | 7.4600 | 1.7500 | 2.2600 | -64.85% |
| 2021 | 14.5458 | 14.5200 | 23.5300 | 5.6700 | 6.4300 | -54.99% |
| 2020 | 13.3243 | 13.6150 | 21.3200 | 9.0300 | 14.2850 | 1.38% |
| 2019 | 16.0534 | 11.8500 | 20.5600 | 11.6500 | 14.0900 | 26.48% |
| 2018 | 16.9450 | 20.1550 | 26.6900 | 9.0000 | 11.1400 | -42.67% |
| 2017 | 17.1065 | 10.1000 | 26.5800 | 8.9500 | 19.4300 | 95.87% |
| 2016 | 11.5152 | 14.7900 | 16.3700 | 7.3400 | 9.9200 | -36.94% |
| 2015 | 18.3820 | 25.0100 | 26.3500 | 10.9000 | 15.7300 | -36.52% |
| 2014 | 14.3080 | 12.0600 | 24.7800 | 9.9400 | 24.7800 | 119.49% |
| 2013 | 6.4532 | 5.3900 | 13.2300 | 3.7600 | 11.2900 | 117.53% |
| 2012 | 8.6929 | 4.0000 | 13.2500 | 3.9900 | 5.1900 | 31.39% |
| 2011 | 4.8167 | 8.5000 | 8.5000 | 3.1700 | 3.9500 | -52.06% |
| 2010 | 6.8037 | 7.2900 | 8.7700 | 5.2400 | 8.2400 | 17.38% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.644B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $226.106B | 26.06 |
| EssilorLuxottica (ESLOY) | France | $168.548B | 0.00 |
| Boston Scientific (BSX) | United States | $150.853B | 34.49 |
| Stryker (SYK) | United States | $137.722B | 27.34 |
| Medtronic (MDT) | Ireland | $123.497B | 17.41 |
| Lonza Group Ag (LZAGY) | Switzerland | $47.264B | 0.00 |
| Agilent Technologies (A) | United States | $40.971B | 26.52 |
| ResMed (RMD) | United States | $35.713B | 24.72 |
| GE HealthCare Technologies (GEHC) | United States | $32.173B | 15.39 |
| Koninklijke Philips (PHG) | Netherlands | $26.943B | 17.60 |
| Insulet (PODD) | United States | $23.075B | 71.62 |
| Terumo (TRUMY) | Japan | $22.623B | 25.47 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.567B | 10.96 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.901B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.361B | 0.00 |
| Baxter (BAX) | United States | $9.135B | 7.37 |
| Bio-Rad Laboratories (BIO) | United States | $8.202B | 29.49 |
| Demant (WILYY) | Denmark | $7.346B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $3.481B | 10.61 |
| Haemonetics (HAE) | United States | $3.479B | 15.48 |
| ICU Medical (ICUI) | United States | $3.321B | 21.08 |
| Envista Holdings (NVST) | United States | $3.142B | 18.03 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.120B | 0.00 |
| Prestige Consumer Healthcare (PBH) | United States | $2.836B | 12.93 |
| LeMaitre Vascular (LMAT) | United States | $1.973B | 39.72 |
| Perrigo (PRGO) | Ireland | $1.866B | 4.68 |
| Phibro Animal Health (PAHC) | United States | $1.826B | 18.24 |
| AtriCure (ATRC) | United States | $1.647B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.433B | 9.21 |
| Neogen (NEOG) | United States | $1.395B | 26.75 |
| Curaleaf Holdings (CURLF) | Canada | $1.345B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.291B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.264B | 18.29 |
| Green Thumb Industries (GTBIF) | United States | $1.186B | 52.00 |
| Tilray Brands (TLRY) | Canada | $1.157B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.156B | 343.00 |
| InMode (INMD) | Israel | $0.879B | 9.94 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.854B | 0.00 |
| Valneva SE (VALN) | France | $0.764B | 0.00 |
| Surmodics (SRDX) | United States | $0.612B | 0.00 |
| CeriBell (CBLL) | United States | $0.478B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.474B | 16.33 |
| Evolus (EOLS) | United States | $0.451B | 0.00 |
| SNDL (SNDL) | Canada | $0.439B | 0.00 |
| BillionToOne (BLLN) | $0.417B | 0.00 | |
| Cresco Labs (CRLBF) | United States | $0.319B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.318B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Brainsway (BWAY) | Israel | $0.297B | 50.60 |
| Cerus (CERS) | United States | $0.294B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.280B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.260B | 0.00 |
| Quanterix (QTRX) | United States | $0.258B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.252B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.244B | 143.33 |
| Viemed Healthcare (VMD) | United States | $0.239B | 19.06 |
| High Tide (HITI) | Canada | $0.229B | 0.00 |
| Owens & Minor (OMI) | United States | $0.224B | 2.24 |
| TriSalus Life Sciences (TLSI) | United States | $0.223B | 0.00 |
| Organigram Global (OGI) | Canada | $0.201B | 0.00 |
| Exagen (XGN) | United States | $0.192B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.188B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.176B | 15.52 |
| FitLife Brands (FTLF) | United States | $0.165B | 20.35 |
| OraSure Technologies (OSUR) | United States | $0.161B | 0.00 |
| Apyx Medical (APYX) | United States | $0.154B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.146B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.133B | 0.00 |
| Biote (BTMD) | United States | $0.118B | 5.16 |
| Quipt Home Medical (QIPT) | United States | $0.098B | 0.00 |
| MacroGenics (MGNX) | United States | $0.096B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 0.00 |
| Fonar (FONR) | United States | $0.089B | 12.96 |
| Sharps Technology (STSS) | United States | $0.081B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.075B | 0.00 |
| Agape ATP (ATPC) | $0.065B | 0.00 | |
| Nephros (NEPH) | United States | $0.058B | 41.77 |
| ImmuCell (ICCC) | United States | $0.044B | 18.89 |
| Jin Medical (ZJYL) | China | $0.044B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.041B | 0.00 |
| Veru (VERU) | United States | $0.037B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.034B | 0.00 |
| Modular Medical (MODD) | United States | $0.033B | 0.00 |
| United-Guardian (UG) | United States | $0.028B | 14.19 |
| Bonk (BNKK) | United States | $0.024B | 0.00 |
| Zynex (ZYXI) | United States | $0.017B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.011B | 0.00 |
| INLIF (INLF) | China | $0.010B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Flora Growth (FLGC) | United States | $0.006B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.005B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| Functional Brands (MEHA) | $0.003B | 0.00 | |
| Akanda (AKAN) | Canada | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |